CLL pathogenesis: microenviromental and genetics

D. Colomer

The role of microRNA in CLL pathogenesis

C.M. Croce

Predictive biomarkers

D. Rossi

FCR

J.A. Burger

Chlorambucil plus anti-CD20

M. Hallek

Comorbidities and other cancers

A. Ferrajoli

Ibrutinib

J.A. Burger

Idelalisib

S.M. O’Brien

Second generation BTK Inhibitor

P. Hillmen

Management of side-effects during targeted therapy

M.S. Davids

Drivers of treatment patterns in patients stopping ibrutinib or idelalisib

A.R. Mato

Is there a potential risk of an increased rate of Richter Syndrome with the advent of targeted therapy?

D. Rossi

Treatment approach in the era of novel therapies

T.A. Eyre

When and how to use allotransplant

P. Dreger

Next-generation BTK inhibitors: Zanubrutinib

C. Tam

Next-generation BTK inhibitors: ARQ531

D.M. Stephens

Other PI3K inhibitors: Duvelisib

S.M. O’Brien

Other PI3K inhibitors: Umbralisib

A.R. Mato

The stop of the treatment with the new targeted therapies: will it be possible in the future?

P. Hillmen

Which are the best combinations of therapies using targeted agents?

J.A. Burger

How should we sequence these novel agents?

M.S. Davids